Form 4: Kineta CFO Keith Baker Reports Stock Option Grant

Keith Baker, CFO of Kineta, Inc., reports the acquisition of stock options.

Summary

• On April 14, 2024, Keith Baker, the Chief Financial Officer of Kineta, Inc., was granted stock options to purchase 225,000 shares of common stock at an exercise price of $0.36 per share.
• 25% of the shares are immediately vested and exercisable.
• An additional 25% will vest monthly over the following 36 months, contingent upon continuous service.
• The remaining 50% will vest upon the achievement of a Transaction or Qualified Transaction.
• A Qualified Transaction is defined as either a capital raise commitment exceeding $25 million with at least $10 million upon closing, or a partnership event resulting in an upfront cash payment of at least $15 million with future milestones exceeding $100 million.
• The options expire on April 13, 2034.

Sentiment

Score: 7

Explanation: The document is neutral to positive. It reports a standard executive compensation practice. The vesting conditions tied to financial milestones suggest confidence in the company's future prospects.

Positives

• The stock option grant incentivizes the CFO to drive company performance and achieve key milestones.
• The vesting schedule is tied to both continued service and the achievement of significant financial or strategic events, aligning the CFO's interests with those of the shareholders.

Risks

• The vesting of a significant portion of the options is contingent on achieving a Qualified Transaction, which may not occur.
• If the CFO leaves the company before the options fully vest, a portion of the options may be forfeited.

Future Outlook

The vesting of a significant portion of the options is tied to future financial or strategic events, indicating an expectation of potential capital raising or partnership deals.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with those of shareholders. The specific terms of the grant, such as the vesting schedule and performance-based conditions, are tailored to the company's specific goals and circumstances.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their compensation packages.
• The vesting schedules and performance metrics attached to these options vary widely depending on the company's stage of development and strategic priorities.

Stakeholder Impact

• The stock option grant aligns the CFO's interests with those of shareholders, potentially leading to increased shareholder value.
• The potential for a capital raise or partnership event could impact shareholders, employees, and other stakeholders.

Key Dates

Keywords

stock options, Kineta, Keith Baker, CFO, Form 4, vesting, Qualified Transaction, capital raise, partnership